Albert Seymour - 06 Sep 2023 Form 4 Insider Report for Homology Medicines, Inc. (QTTB)

Reporting relationship: President and Chief Executive Officer, Director
Issuer ticker: QTTB
Reported as of: 06 Sep 2023
Net transaction value: -$1,665
SEC form: 4
Accepted by SEC: 08 Sep 2023, 16:44:26 UTC
Prior SEC filing: 27 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Paul Alloway, Attorney-in-Fact for Albert Seymour

Key filing fact

Albert Seymour filed Form 4 for Homology Medicines, Inc. (QTTB) on 08 Sep 2023.

Key facts

This page summarizes Albert Seymour's Form 4 filing for Homology Medicines, Inc. (QTTB).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Sep 2023, 16:44.

Change

Previous filing in this sequence was filed on 27 Feb 2023.
Current net transaction value: -$1,665.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FIXX transaction

Common Stock

Options Exercise

Transaction value
Shares: +4,620
Change %: +3.1%
Price
Shares after: 152,322
Date: 06 Sep 2023
Ownership: Direct
Footnotes: F1

FIXX transaction

Common Stock

Sale

Transaction value: $1,665
Shares: -1,448
Change %: -0.95%
Price: $1.15
Shares after: 150,874
Date: 06 Sep 2023
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FIXX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -4,620
Change %: -33%
Price: $0.000000
Shares after: 9,380
Date: 06 Sep 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,620
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.

Footnote F2

The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of RSUs.

Footnote F3

The RSUs will vest and settle as to one third of the RSUs on each of the first three anniversaries of September 6, 2022 so that such RSUs will become fully vested on September 6, 2025. The RSUs have no expiration date.

SEC remarks

President and Chief Executive Officer